Advertisement
Advertisement
CTOR
C
Citius Oncology, Inc. Common Stock
0.57
USDSponsored
-0.01
-1.48%
Mar 25, 16:00 UTC -4
Closed
After-Market
0.58
0.00
+0.52%
CTOR Earnings Reports
Positive Surprise Ratio
CTOR beat 2 of 5 last estimates.
40%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q2 26 (Revenue/ EPS)
$7.14M
/-$0.01
Implied change from Q1 26 (Revenue/ EPS)
+81.14%
/-83.33%
Implied change from Q2 25 (Revenue/ EPS)
--
/-90.91%
Citius Oncology, Inc. Common Stock earnings per share and revenue
On Feb 13, 2026, CTOR reported earnings of -0.06 USD per share (EPS) for Q1 26, missing the estimate of 0.06 USD, resulting in a -198.04% surprise. Revenue reached 3.94 million, compared to an expected 4.46 million, with a -11.67% difference. The market reacted with a +3.39% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.01 USD, with revenue projected to reach 7.14 million USD, implying an decrease of -83.33% EPS, and increase of 81.14% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Precigen, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.01
Surprise
+88.24%
Absci Corporation Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.23
Surprise
-16.04%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
LENZ Therapeutics, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.99
Actual
-$1.15
Surprise
-17.10%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
$0.03
Actual
-$0.11
Surprise
-408.12%
Equillium, Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.06
Actual
-$0.04
Surprise
+35.28%
MaxCyte, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.08
Actual
-$0.06
Surprise
+26.47%
Celcuity Inc. Common Stock
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$1.06
Actual
-$0.97
Surprise
+8.72%
Dyadic International, Inc.
Report Date
Mar 25, 2026 For Q4 25
Estimate
-$0.04
Actual
-$0.06
Surprise
-30.72%
TELA Bio, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.12%
FAQ
What were Citius Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Citius Oncology, Inc. Common Stock reported EPS of -$0.06, missing estimates by -198.04%, and revenue of $3.94M, -11.67% below expectations.
How did the market react to Citius Oncology, Inc. Common Stock's Q1 2026 earnings?
The stock price moved up 3.39%, changed from $1.18 before the earnings release to $1.22 the day after.
When is Citius Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Citius Oncology, Inc. Common Stock's next earnings report?
Based on 3
analysts, Citius Oncology, Inc. Common Stock is expected to report EPS of -$0.01 and revenue of $7.14M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement